Joshua S Siegel
Overview
Explore the profile of Joshua S Siegel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bender D, Nayak S, Siegel J, Hellerstein D, Ercal B, Lenze E
J Clin Psychiatry
. 2025 Feb;
86(1).
PMID: 39928849
To assess the viewpoints of psychedelic practitioners in research settings on approaches to psychological support for psychedelic treatments. An anonymous survey was distributed via email to contacts listed on ClinicalTrials.gov...
2.
Padawer-Curry J, Krentzman O, Kuo C, Wang X, Bice A, Nicol G, et al.
bioRxiv
. 2024 Nov;
PMID: 39605498
Psychedelics hold therapeutic promise for mood disorders due to rapid, sustained results. Human neuroimaging studies have reported dramatic serotonin-2A receptor-(5-HT2AR)-dependent changes in functional brain reorganization that presumably reflect neuromodulation. However,...
3.
Siegel J, Cohen A, Szabo S, Tomioka S, Opler M, Kirkpatrick B, et al.
Psychiatry Res
. 2024 Aug;
340:116105.
PMID: 39151277
Clinical trials in depression lack objective measures. Speech latencies are an objective measure of psychomotor slowing with face validity and empirical support. 'Turn latency' is the response time between speakers....
4.
Cohen A, Rodriguez Z, Opler M, Kirkpatrick B, Milanovic S, Piacentino D, et al.
Psychiatry Res
. 2024 Aug;
340:116104.
PMID: 39137558
We sought to derive an objective measure of psychomotor slowing from speech analytics during a psychiatric interview to avoid potential burden of dedicated neurophysiological testing. Speech latency, which reflects response...
5.
6.
Siegel J, Subramanian S, Perry D, Kay B, Gordon E, Laumann T, et al.
Nature
. 2024 Jul;
632(8023):131-138.
PMID: 39020167
A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials. In animal models,...
7.
Siegel J, Zhong J, Tomioka S, Ogirala A, Faraone S, Szabo S, et al.
medRxiv
. 2024 May;
PMID: 38712180
Currently, placebo-controlled clinical trials report mean change and effect sizes, which masks information about heterogeneity of treatment effects (HTE). Here, we present a method to estimate HTE and evaluate the...
8.
Siegel J, Subramanian S, Perry D, Kay B, Gordon E, Laumann T, et al.
medRxiv
. 2023 Sep;
PMID: 37701731
1The relationship between the acute effects of psychedelics and their persisting neurobiological and psychological effects is poorly understood. Here, we tracked brain changes with longitudinal precision functional mapping in healthy...
9.
Siegel J, Pearson C, Lenze E
Mo Med
. 2023 Aug;
120(4):292-298.
PMID: 37609458
The 21 century has brought novel therapies and new therapeutic targets for major depressive disorder (MDD). Until recently all antidepressant medications targeted monoamines-serotonin, norepinephrine, and dopamine- and their regulatory systems....
10.
Siegel J, Daily J, Perry D, Nicol G
JAMA Psychiatry
. 2022 Dec;
80(1):77-83.
PMID: 36477830
Importance: Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus on treatment models, education and guidance for health care professionals,...